Avedro to Present Research on Proprietary Corneal Cross-Linking Technologies at 2019 ARVO Annual Meeting
WALTHAM, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (Avedro), today announced that three abstracts highlighting proprietary cross-linking technologies being developed by Avedro have been accepted for poster presentations at the upcoming 2019 Association for Research in Vision and Ophthalmology (ARVO) Meeting being held April 28-May 2 in Vancouver, BC. ARVO is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries.
The presentations include data on technologies relating to Avedro’s proprietary Epi-On (epithelial-on) and PiXL corneal cross-linking procedures. Avedro’s Epi-On procedure is designed to treat the cornea without the need to remove the epithelium and is currently being studied in a U.S. pivotal Phase 3 clinical trial for the treatment of progressive keratoconus, a debilitating and typically progressive eye disease that, if left untreated, can lead to loss of vision and even blindness. The PiXL procedure is in development to non-invasively improve vision for patients with presbyopia, the normal loss of near focusing ability that occurs with age, which we estimate affects more than 50 million people in the United States.
“Avedro is committed to developing important new technologies for corneal cross-linking as we pursue next-generation solutions for vision loss,” said Reza Zadno, PhD, President and Chief Executive Officer of Avedro. “Our ability to conduct clinically relevant research and collaborate with practitioners in the development of new technologies shows our leadership in the field of corneal cross-linking.”
The scientific poster presentations are scheduled as follows:
Sunday, April 28
- 8:00-9:45 AM – Biomechanical Impact of Drug Formulation, Supplemental Oxygen, and UV Delivery on Epi-On CXL. Adler DC, Hill J, Liu C, Deardorff P, Raizman M, Rajpal R. Poster #317-B0509.
- 8:00-9:45 AM – Stromal Oxygen Dynamics During High-Irradiance Epi-On Corneal Crosslinking. Hill J, Liu C, Deardorff P, Thompson V, Gore D, Adler DC. Poster #325-B0517.
- 8:00-9:45 AM – Impact of Eye Motion and Active vs. Passive Eye Tracking on Refractive Crosslinking. Usher D, Mukherjee A, Smirnov M, Hill J, Eddington W, Liu C, Adler DC. Poster #327-B0519.
Avedro is a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Avedro’s proprietary Avedro Corneal Remodeling Platform is designed to strengthen, stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions. The Avedro Corneal Remodeling Platform is comprised of Avedro’s KXL and Mosaic systems, each of which delivers ultraviolet A light, and a suite of proprietary single-use riboflavin drug formulations, which, when applied together to the cornea, induce a biochemical reaction called corneal collagen cross-linking.
| Avedro Contact: | Investor Contact: |
| David Iannetta | Greg Chodaczek or Lynn Lewis |
| Phone: 781-768-3400 | Phone: 646-924-1769 |
| info@avedro.com | investors@avedro.com |
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
